GLTO Galecto

Galecto to Participate in Upcoming Investor Conferences

Galecto to Participate in Upcoming Investor Conferences

BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and severe liver diseases, today announced that the Company management team will participate in the following upcoming investor conferences:

Oppenheimer 35th Annual Healthcare Life Sciences Conference

Format: Corporate Presentation and One-on-One Meetings

Date and Time: Wednesday, February 12 at 8:40-9:10 AM  

Location: Virtual

A live webcast of the presentation will be available via the Upcoming Events section of the Company’s investor relations website at . An archived replay will be accessible for 90 days following the event.

Leerink Partners Global Healthcare Conference

Format: One-on-One meetings

Date and Time: Wednesday, March 12

Location: Miami Beach, Florida

37th Annual ROTH Conference

Format: Corporate Presentation and One-on-One Meetings

Date and Time: Monday, March 17, and Tuesday, March 18

Location: Dana Point, CA

About Galecto

Galecto is a clinical-stage biopharmaceutical company committed to realizing the promise of novel treatments for cancer and liver diseases. The Company’s pipeline consists of first-in-class small molecule drug candidates that target cancer and fibrosis signaling pathways, including (i) an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis; (ii) an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications; and (iii) as recently announced, a preclinical dual inhibitor of ENL-YEATS and FLT3 (BRM-1420) for multiple genetic subsets of AML, which Galecto acquired from Bridge Medicines. Galecto intends to use its website as a means of disclosing material non-public information. For regular updates about Galecto, visit

For more information, contact:

Investors Contact:

Sandya von der Weid



EN
06/02/2025

Underlying

GLTOGalecto

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Galecto

 PRESS RELEASE
Free
GLTO GALECTO

Galecto Announces Closing of Public Offering and Full Exercise of the ...

Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced the closing of its previously announced underwritten public offering of 16,644,737 shares of its common stock, including the full exercise of the underwriters’ option to purchase up to 2,171,052 additional s...

February 12, 2026 1 EN
 PRESS RELEASE
Free
GLTO GALECTO

Galecto Announces Pricing of $275 Million Underwritten Public Offering

Galecto Announces Pricing of $275 Million Underwritten Public Offering BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced the pricing of its previously announced underwritten public offering of shares of its common stock. Galecto is selling a total of 14,473,685 shares of common stock at a public offering price of $19.00 per share. In addition, Galecto has granted the underwriters a 30-day option to purchase an a...

February 11, 2026 1 EN
 PRESS RELEASE
Free
GLTO GALECTO

Galecto Announces Proposed Underwritten Public Offering of Common Stoc...

Galecto Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, Series C non-voting convertible preferred stock. All of the securities are being offered by Galecto. In addition, Galecto i...

February 10, 2026 1 EN
 PRESS RELEASE
Free
GLTO GALECTO

Galecto Highlights Key Strategic Priorities and Anticipated 2026 Miles...

Galecto Highlights Key Strategic Priorities and Anticipated 2026 Milestones DMR-001, a potentially best-in-class mutant calreticulin (“mutCALR”) targeting monoclonal antibody, on track for expected IND submission, or equivalent, in mid-2026 with anticipated first-in-human dosing via subcutaneous administrationRecent addition of deep hematology/oncology drug development experience with the appointment of a Chief Operating Officer and Chief Medical OfficerPipeline of additional candidates advancing to the clinic, with first IND submission of DMR-002 expected in second half of 2026Cash balance...

January 12, 2026 1 EN
 PRESS RELEASE
Free
GLTO GALECTO

Galecto Announces Key Additions to Leadership Team

Galecto Announces Key Additions to Leadership Team Deep hematology/oncology drug development experience added with the appointment of Sherwin Sattarzadeh as Chief Operating Officer and Becker Hewes as Chief Medical Officer DMR-001, a potentially best-in-class mutant calreticulin (“mutCALR”) targeting monoclonal antibody, on track for IND submission in mid-2026 with anticipated first-in-human dosing via subcutaneous administration Cash balance, including $285 million raised in November 2025 PIPE, provides financial runway into 2029 to support multiple data milestones, including Ph1 clinica...

January 6, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch